Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Aged ≥ 18 years.
Clinical diagnosis of nonsegmental vitiligo and meet the following:
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
Willingness to avoid pregnancy or fathering children.
Exclusion criteria
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
444 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Incyte Corporation Call Center (ex-US); Incyte Corporation Call Center (US)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal